表紙:血液悪性腫瘍検査市場- 世界の産業規模、シェア、動向、機会、予測、2017年-2027年、成分別、技術別、治療適応症別、エンドユーザー別、企業別、地域別セグメント
市場調査レポート
商品コード
1289650

血液悪性腫瘍検査市場- 世界の産業規模、シェア、動向、機会、予測、2017年-2027年、成分別、技術別、治療適応症別、エンドユーザー別、企業別、地域別セグメント

Hematologic Malignancies Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented By Component, By Technique, By Therapeutic Indication, By End User, By company and By Region

出版日: | 発行: TechSci Research | ページ情報: 英文 114 Pages | 納期: 2~3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=151.55円

こちらのレポートには、数時間(ご購入金額の10%)分のアナリストへの質問/追加調査サービスが含まれております。

血液悪性腫瘍検査市場- 世界の産業規模、シェア、動向、機会、予測、2017年-2027年、成分別、技術別、治療適応症別、エンドユーザー別、企業別、地域別セグメント
出版日: 2023年06月01日
発行: TechSci Research
ページ情報: 英文 114 Pages
納期: 2~3営業日
  • 全表示
  • 概要
  • 目次
概要

世界の血液悪性腫瘍検査市場は、予測期間2023-2027年に目覚ましい成長を遂げると予測されています。

血液がんの発生件数の増加や技術の広範な開拓などの主要因が、市場の成長を後押ししています。血液悪性腫瘍は、血液、骨髄、リンパ節に影響を及ぼすがんです。白血病、リンパ腫、骨髄腫は一般的な血液がんの種類です。血液悪性腫瘍検査は、血液がんの診断に役立つ医療検査方法です。その他の市場成長要因としては、研究開発活動の活発化、政府からの助成金の増加、個別化医療の重視、患者や医療従事者の意識の高まり、高齢化社会の到来、無機的成長戦略の採用の増加、製品発表の増加、新興サブマーケットへの大きな可能性が挙げられます。

血液関連疾患の発生率の増加

白血病、リンパ腫、骨髄腫などの血液関連疾患の増加が、世界的に市場の成長を後押ししています。米国がん協会によると、米国では約3分に1人の割合で白血病、リンパ腫、骨髄腫と診断されています。血液がんの患者数は増加しており、血液がんの早期発見と治療の必要性が高まっていることが、市場の成長を後押ししています。血液がんは、世界中で5番目に多い悪性腫瘍であり、がんによる死亡の2番目の主な理由となっています。例えば、世界中で年間30万人以上が白血病、40万人以上がリンパ腫と診断されています。

技術の進化と研究開発活動の活発化

ヘルスケア分野における新技術の進化は、市場の成長を加速させています。デジタルPCR、次世代シーケンサー、細胞遺伝学など、革新的な新技術の導入が進み、市場の成長を強化しています。このような開発により、治療にかかる費用や時間を最小限に抑え、人間の生活の質を向上させることができるようになっています。さらに、研究開発活動の活発化も市場の成長を後押ししています。

無機的な成長戦略の採用の増加

M&A、協業、パートナーシップなどの無機的な成長戦略の高まりや、市場プレイヤーによる製品発表の増加が、市場の成長を後押ししています。例えば、2021年、Natera, Inc.とPersonalis, Inc.は、PersonisのNeXT腫瘍プロファイリングおよび診断製品とNateraの個別化ctDNAプラットフォームSignateraを結合して治療モニタリングおよび分子残存病変評価を行うことにより個別化オンコロジーにおいて提携しました。同様に、2018年にはアボット社がヘマトロジーシステムを組み込んだhシリーズを発売し、それ以降、臨床検査室に数々の変化をもたらしています。

利用可能なカスタマイズ

与えられた市場データをもとに、TechSci Researchは企業の特定のニーズに応じてカスタマイズを提供します。本レポートでは、以下のカスタマイズが可能です:

企業情報

  • 追加の市場プレイヤー(最大5名)の詳細な分析とプロファイリング

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 血液悪性腫瘍検査の世界市場に対するCOVID-19の影響

第5章 顧客の声

第6章 臨床試験分析

第7章 血液悪性腫瘍検査の世界市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェアと予測
    • コンポーネント別(キット/サービス)
    • 技術別(次世代シーケンサー(NGS)、ポリメラーゼ連鎖反応(PCR)、蛍光in-situハイブリダイゼーション(FISH)、免疫組織化学(IHC)、その他)
    • 治療適応症別(白血病、リンパ腫、多発性骨髄腫、骨髄増殖性新生物、その他)
    • エンドユーザー別(病院・クリニック、診断研究所、学術・研究機関、その他)
    • 企業別(2021年)
    • 地域別
  • 市場マップ

第8章 北米の血液悪性腫瘍検査市場の展望

  • 市場規模・予測
    • 金額別
  • 市場シェアと予測
    • コンポーネント別
    • 技術別
    • 治療適応症別
    • エンドユーザー別
    • 国別
  • 北米国別分析
    • 米国
    • カナダ
    • メキシコ

第9章 欧州血液悪性腫瘍検査市場の展望

  • 市場規模・予測
    • 金額ベース
  • 市場シェアと予測
    • コンポーネント別
    • 技術別
    • 治療適応症別
    • エンドユーザー別
    • 国別
  • 欧州国別分析
    • フランス
    • ドイツ
    • 英国
    • イタリア
    • スペイン

第10章 アジア太平洋地域の血液悪性腫瘍検査市場の展望

  • 市場規模・予測
    • 金額ベース
  • 市場シェアと予測
    • コンポーネント別
    • 技術別
    • 治療適応症別
    • エンドユーザー別
    • 国別
  • アジア太平洋地域国別分析
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア

第11章 南米血液悪性腫瘍検査市場の展望

  • 市場規模・予測
    • 金額ベース
  • 市場シェアと予測
    • コンポーネント別
    • 技術別
    • 治療適応症別
    • エンドユーザー別
    • 国別
  • 南米の国別分析
    • ブラジル
    • アルゼンチン
    • コロンビア

第12章 中東・アフリカ血液悪性腫瘍検査市場の展望

  • 市場規模・予測
    • 金額ベース
  • 市場シェアと予測
    • コンポーネント別
    • 技術別
    • 治療適応症別
    • エンドユーザー別
    • 国別
  • MEA:国別分析
    • 南アフリカ
    • サウジアラビア
    • UAE
    • トルコ
    • エジプト

第13章 市場力学

  • 促進要因
  • 課題

第14章 市場の動向と開拓

第15章 競合情勢

  • Abbott Laboratories, Inc.
  • Asuragen Inc.
  • Bio-Rad Laboratories, Inc.
  • Adaptive Biotechnologies Corporation
  • F.Hoffmann-La-Roche AG
  • Illumina, Inc.
  • ICON plc.
  • Invitae Corporation
  • Laboratory Corporation of America Holdings
  • Invivoscribe, Inc.

第16章 戦略的提言

目次
Product Code: 13004

The global hematologic malignancies testing market is anticipated to observe impressive growth during the forecast period 2023-2027. The major factors, including growing occurrences of blood cancer and extensive development in technology, are fueling the growth of the market. Hematologic malignancies are cancers that affect the blood, bone marrow, and lymph nodes. Leukemia, lymphoma, and myeloma are the common types of blood cancer. Hematologic malignancies testing is a medical testing method that helps to diagnose blood cancer. The other factors supporting the market's growth are a rise in R&D activities, increasing favorable government funding, rising emphasis on personalized medicine, increasing awareness among patients and healthcare professionals, rise in aging population base, growing adoption of inorganic growth strategies, an increasing number of product launches, and immense potential for emerging submarkets.

Increasing Occurrence of Blood-Related Disorders

The growing incidences of blood-related disorders, such as leukemia, lymphoma, and myeloma, are bolstering the growth of the market globally. According to the American Cancer Society, in the United States, around every 3 minutes, a person is diagnosed with leukemia, lymphoma, and myeloma. Owing to the rise in the number of patients who have hematologic cancer, the surge in the need for early detection and treatment of blood cancers is augmenting the growth of the market. Blood cancers are the fifth most common malignancy across the world and the second primary reason for cancer death. For instance, more than 300,000 people are diagnosed yearly with leukemia and 400,000 with lymphoma across the globe.

Technological Advancements and Rise in R&D Activities

The evolution of new technologies in the healthcare sector is surging the growth of the market. The increasing adoption of new innovative technologies, such as digital PCR, next-generation sequencing, cytogenetics, and others, is strengthening the growth of the market. The developments are helping to minimize the cost and time of treatment and improve the quality of human life. Moreover, the rise in R&D activities is propelling the growth of the market.

Increasing Adoption of Inorganic Growth Strategies

Growing inorganic growth strategies such as mergers, acquisitions, collaborations, partnerships, and an increasing number of product launches by market players are bolstering the growth of the market. For instance, in 2021, Natera, Inc., and Personalis, Inc. partnered in personalized oncology by coupling Personalis' NeXT tumor profiling and diagnostic products with Natera's personalized ctDNA platform Signatera for treatment monitoring and molecular residual disease assessment. Similarly, in 2018, Abbott launched an h-series incorporating a hematology system and has brought numerous changes in the clinical laboratories since then.

Market Segmentation

The global hematologic malignancies testing market is segmented into component, technique, therapeutic indication, end user, and company. Based on components, the market is divided into kits and services. Based on kits, the market is further divided into gene panels, molecular clonality testing, translocation testing, mutation testing, and others. Based on technique, the market is divided into next-generation sequencing (NGS), polymerase chain reaction (PCR), fluorescence in-situ hybridization (FISH), immunohistochemistry (IHC), and others. Based on therapeutic indication, the market is divided into leukemia, lymphoma, multiple myeloma, myeloproliferative neoplasms, and others. Based on end-user, the market is divided into hospitals & clinics, diagnostic laboratories, academic & research institutions, and others. In terms of country, the United States is expected to be a lucrative market in the forecast period due to rising incidences of blood cancers in the country.

Market Players

Abbott Laboratories, Inc., Asuragen Inc., Bio-Rad Laboratories, Inc., Adaptive Biotechnologies Corporation, F.Hoffmann-La-Roche AG, Illumina, Inc., ICON plc., Invitae Corporation, Laboratory Corporation of America Holdings, and Invivoscribe, Inc. are some of the leading companies operating in the market.

Report Scope

In this report, global hematologic malignancies testing market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Hematologic Malignancies Testing Market, By Component:

  • Kits
    • Gene Panels
    • Molecular Clonality Testing
    • Translocation Testing
    • Mutation Testing
    • Others
  • Services

Hematologic Malignancies Testing Market, By Component:

  • Next-Generation Sequencing (NGS)
  • Polymerase Chain Reaction (PCR)
  • Fluorescence In-Situ Hybridization (FISH)
  • Immunohistochemistry (IHC)
  • Others

Hematologic Malignancies Testing Market, By Therapeutic Indication:

  • Leukemia
  • Lymphoma
  • Multiple Myeloma
  • Myeloproliferative Neoplasms
  • Others

Hematologic Malignancies Testing Market, By End User:

  • Hospitals & Clinics
  • Diagnostic Laboratories
  • Academic & Research Institutions
  • Others

Hematologic Malignancies Testing Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • Europe & CIS
    • Germany
    • France
    • United Kingdom
    • Spain
    • Italy
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Egypt
    • Turkey

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global Hematologic Malignancies Testing Market

Available Customizations

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Impact of COVID-19 on Global Hematologic Malignancies Testing Market

5. Voice of Customer

6. Clinical Trial Analysis

7. Global Hematologic Malignancies Testing Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Component (Kits v/s Services)
      • 7.2.1.1. By Kits (Gene Panels, Molecular Clonality Testing, Translocation Testing, Mutation Testing, Others)
    • 7.2.2. By Technique (Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescence In-Situ Hybridization (FISH), Immunohistochemistry (IHC), Others)
    • 7.2.3. By Therapeutic Indication (Leukemia, Lymphoma, Multiple Myeloma, Myeloproliferative Neoplasms, Others)
    • 7.2.4. By End User (Hospitals & Clinics, Diagnostic Laboratories, Academic & Research Institutions, Others)
    • 7.2.5. By Company (2021)
    • 7.2.6. By Region
  • 7.3. Market Map

8. North America Hematologic Malignancies Testing Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Component (Kits v/s Services)
      • 8.2.1.1. By Kits (Gene Panels, Molecular Clonality Testing, Translocation Testing, Mutation Testing, Others)
    • 8.2.2. By Technique (Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescence In-Situ Hybridization (FISH), Immunohistochemistry (IHC), Others)
    • 8.2.3. By Therapeutic Indication (Leukemia, Lymphoma, Multiple Myeloma, Myeloproliferative Neoplasms, Others)
    • 8.2.4. By End User (Hospitals & Clinics, Diagnostic Laboratories, Academic & Research Institutions, Others)
    • 8.2.5. By Country
  • 8.3. North America: Country Analysis
    • 8.3.1. United States Hematologic Malignancies Testing Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Component
        • 8.3.1.2.2. By Technique
        • 8.3.1.2.3. By Therapeutic Indication
        • 8.3.1.2.4. By End User
    • 8.3.2. Canada Hematologic Malignancies Testing Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Component
        • 8.3.2.2.2. By Technique
        • 8.3.2.2.3. By Therapeutic Indication
        • 8.3.2.2.4. By End User
    • 8.3.3. Mexico Hematologic Malignancies Testing Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Component
        • 8.3.3.2.2. By Technique
        • 8.3.3.2.3. By Therapeutic Indication
        • 8.3.3.2.4. By End User

9. Europe Hematologic Malignancies Testing Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Component (Kits v/s Services)
      • 9.2.1.1. By Kits (Gene Panels, Molecular Clonality Testing, Translocation Testing, Mutation Testing, Others)
    • 9.2.2. By Technique (Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescence In-Situ Hybridization (FISH), Immunohistochemistry (IHC), Others)
    • 9.2.3. By Therapeutic Indication (Leukemia, Lymphoma, Multiple Myeloma, Myeloproliferative Neoplasms, Others)
    • 9.2.4. By End User (Hospitals & Clinics, Diagnostic Laboratories, Academic & Research Institutions, Others)
    • 9.2.5. By Country
  • 9.3. Europe: Country Analysis
    • 9.3.1. France Hematologic Malignancies Testing Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Component
        • 9.3.1.2.2. By Technique
        • 9.3.1.2.3. By Therapeutic Indication
        • 9.3.1.2.4. By End User
    • 9.3.2. Germany Hematologic Malignancies Testing Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Component
        • 9.3.2.2.2. By Technique
        • 9.3.2.2.3. By Therapeutic Indication
        • 9.3.2.2.4. By End User
    • 9.3.3. United Kingdom Hematologic Malignancies Testing Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Component
        • 9.3.3.2.2. By Technique
        • 9.3.3.2.3. By Therapeutic Indication
        • 9.3.3.2.4. By End User
    • 9.3.4. Italy Hematologic Malignancies Testing Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Component
        • 9.3.4.2.2. By Technique
        • 9.3.4.2.3. By Therapeutic Indication
        • 9.3.4.2.4. By End User
    • 9.3.5. Spain Hematologic Malignancies Testing Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Component
        • 9.3.5.2.2. By Technique
        • 9.3.5.2.3. By Therapeutic Indication
        • 9.3.5.2.4. By End User

10. Asia-Pacific Hematologic Malignancies Testing Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Component (Kits v/s Services)
      • 10.2.1.1. By Kits (Gene Panels, Molecular Clonality Testing, Translocation Testing, Mutation Testing, Others)
    • 10.2.2. By Technique (Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescence In-Situ Hybridization (FISH), Immunohistochemistry (IHC), Others)
    • 10.2.3. By Therapeutic Indication (Leukemia, Lymphoma, Multiple Myeloma, Myeloproliferative Neoplasms, Others)
    • 10.2.4. By End User (Hospitals & Clinics, Diagnostic Laboratories, Academic & Research Institutions, Others)
    • 10.2.5. By Country
  • 10.3. Asia-Pacific: Country Analysis
    • 10.3.1. China Hematologic Malignancies Testing Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Component
        • 10.3.1.2.2. By Technique
        • 10.3.1.2.3. By Therapeutic Indication
        • 10.3.1.2.4. By End User
    • 10.3.2. India Hematologic Malignancies Testing Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Component
        • 10.3.2.2.2. By Technique
        • 10.3.2.2.3. By Therapeutic Indication
        • 10.3.2.2.4. By End User
    • 10.3.3. Japan Hematologic Malignancies Testing Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Component
        • 10.3.3.2.2. By Technique
        • 10.3.3.2.3. By Therapeutic Indication
        • 10.3.3.2.4. By End User
    • 10.3.4. South Korea Hematologic Malignancies Testing Market Outlook
      • 10.3.4.1. Market Size & Forecast
        • 10.3.4.1.1. By Value
      • 10.3.4.2. Market Share & Forecast
        • 10.3.4.2.1. By Component
        • 10.3.4.2.2. By Technique
        • 10.3.4.2.3. By Therapeutic Indication
        • 10.3.4.2.4. By End User
    • 10.3.5. Australia Hematologic Malignancies Testing Market Outlook
      • 10.3.5.1. Market Size & Forecast
        • 10.3.5.1.1. By Value
      • 10.3.5.2. Market Share & Forecast
        • 10.3.5.2.1. By Component
        • 10.3.5.2.2. By Technique
        • 10.3.5.2.3. By Therapeutic Indication
        • 10.3.5.2.4. By End User

11. South America Hematologic Malignancies Testing Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Component (Kits v/s Services)
      • 11.2.1.1. By Kits (Gene Panels, Molecular Clonality Testing, Translocation Testing, Mutation Testing, Others)
    • 11.2.2. By Technique (Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescence In-Situ Hybridization (FISH), Immunohistochemistry (IHC), Others)
    • 11.2.3. By Therapeutic Indication (Leukemia, Lymphoma, Multiple Myeloma, Myeloproliferative Neoplasms, Others)
    • 11.2.4. By End User (Hospitals & Clinics, Diagnostic Laboratories, Academic & Research Institutions, Others)
    • 11.2.5. By Country
  • 11.3. South America: Country Analysis
    • 11.3.1. Brazil Hematologic Malignancies Testing Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Component
        • 11.3.1.2.2. By Technique
        • 11.3.1.2.3. By Therapeutic Indication
        • 11.3.1.2.4. By End User
    • 11.3.2. Argentina Hematologic Malignancies Testing Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Component
        • 11.3.2.2.2. By Technique
        • 11.3.2.2.3. By Therapeutic Indication
        • 11.3.2.2.4. By End User
    • 11.3.3. Colombia Hematologic Malignancies Testing Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Component
        • 11.3.3.2.2. By Technique
        • 11.3.3.2.3. By Therapeutic Indication
        • 11.3.3.2.4. By End User

12. Middle East and Africa Hematologic Malignancies Testing Market Outlook

  • 12.1. Market Size & Forecast
    • 12.1.1. By Value
  • 12.2. Market Share & Forecast
    • 12.2.1. By Component (Kits v/s Services)
      • 12.2.1.1. By Kits (Gene Panels, Molecular Clonality Testing, Translocation Testing, Mutation Testing, Others)
    • 12.2.2. By Technique (Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescence In-Situ Hybridization (FISH), Immunohistochemistry (IHC), Others)
    • 12.2.3. By Therapeutic Indication (Leukemia, Lymphoma, Multiple Myeloma, Myeloproliferative Neoplasms, Others)
    • 12.2.4. By End User (Hospitals & Clinics, Diagnostic Laboratories, Academic & Research Institutions, Others)
    • 12.2.5. By Country
  • 12.3. MEA: Country Analysis
    • 12.3.1. South Africa Hematologic Malignancies Testing Market Outlook
      • 12.3.1.1. Market Size & Forecast
        • 12.3.1.1.1. By Value
      • 12.3.1.2. Market Share & Forecast
        • 12.3.1.2.1. By Component
        • 12.3.1.2.2. By Technique
        • 12.3.1.2.3. By Therapeutic Indication
        • 12.3.1.2.4. By End User
    • 12.3.2. Saudi Arabia Hematologic Malignancies Testing Market Outlook
      • 12.3.2.1. Market Size & Forecast
        • 12.3.2.1.1. By Value
      • 12.3.2.2. Market Share & Forecast
        • 12.3.2.2.1. By Component
        • 12.3.2.2.2. By Technique
        • 12.3.2.2.3. By Therapeutic Indication
        • 12.3.2.2.4. By End User
    • 12.3.3. UAE Hematologic Malignancies Testing Market Outlook
      • 12.3.3.1. Market Size & Forecast
        • 12.3.3.1.1. By Value
      • 12.3.3.2. Market Share & Forecast
        • 12.3.3.2.1. By Component
        • 12.3.3.2.2. By Technique
        • 12.3.3.2.3. By Therapeutic Indication
        • 12.3.3.2.4. By End User
    • 12.3.4. Turkey Hematologic Malignancies Testing Market Outlook
      • 12.3.4.1. Market Size & Forecast
        • 12.3.4.1.1. By Value
      • 12.3.4.2. Market Share & Forecast
        • 12.3.4.2.1. By Component
        • 12.3.4.2.2. By Technique
        • 12.3.4.2.3. By Therapeutic Indication
        • 12.3.4.2.4. By End User
    • 12.3.5. Egypt Hematologic Malignancies Testing Market Outlook
      • 12.3.5.1. Market Size & Forecast
        • 12.3.5.1.1. By Value
      • 12.3.5.2. Market Share & Forecast
        • 12.3.5.2.1. By Component
        • 12.3.5.2.2. By Technique
        • 12.3.5.2.3. By Therapeutic Indication
        • 12.3.5.2.4. By End User

13. Market Dynamics

  • 13.1. Drivers
  • 13.2. Challenges

14. Market Trends & Developments

15. Competitive Landscape

  • 15.1. Abbott Laboratories, Inc.
  • 15.2. Asuragen Inc.
  • 15.3. Bio-Rad Laboratories, Inc.
  • 15.4. Adaptive Biotechnologies Corporation
  • 15.5. F.Hoffmann-La-Roche AG
  • 15.6. Illumina, Inc.
  • 15.7. ICON plc.
  • 15.8. Invitae Corporation
  • 15.9. Laboratory Corporation of America Holdings
  • 15.10. Invivoscribe, Inc.

16. Strategic Recommendations